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E-mail: guido.antonelli@uniroma1.itInfections with a variety of viruses, bacteria and parasites are
associated with a high cancer risk [1]. Indeed, according to
recent estimates, over 2 million new cancer cases per year may
be attributable to infections. A limited number of microor-
ganisms, including Helicobacter pylori, hepatitis B virus, hepatitis
C virus, human papilloma virus, Epstein–Barr virus, human
lymphotropic virus type 1, and human herpesvirus type 8, ac-
count for the large majority of infection-associated cancers.
However, a far larger number of infectious agents are suspected
to play an oncogenic role in malignancies with a range of his-
tological origins. For instance, cytomegalovirus has been sug-
gested to be involved in glioma development [2], BK virus has
been proposed to be a cofactor in the aetiology of prostate
cancers [3], and another polyomavirus, JC virus, has been
suggested to play a role in oncogenesis in the central nervous
system and the colon [4]. On the other hand, advances in the
analysis of bacterial strains associated with colorectal cancer
lesions have emphasized the potential pathogenic relevance of
the colonization of malignant tissues by Fusobacterium nucleatum
[5,6]. Furthermore, in some areas of Southeast Asia, the
prevalence of infections with Opisthorchis viverrini and Clonorchis
sinensis, two liver ﬂukes of the family Opisthorchiidae, has been
epidemiologically associated with the incidence of chol-
angiocarcinoma [7]. Finally, infection with Schistosoma haema-
tobium in Africa and eastern Mediterranean regions has been
associated with bladder cancer [7].
Importantly and intriguingly, the composition of the human
microbiome and its alteration are emerging as crucial de-
terminants in the pathogenesis of a previously unsuspected
range of diseases, including metabolic disorders and cancer [8].
However, an intact intestinal microbiome has also been shown
to be essential for responsiveness to anticancer chemotherapyClinical Microbiology and Infection © 2015 European Society of C[9]. These issues represent the subject of a very active ﬁeld of
research, as it is tempting to speculate that understanding the
diversity of the contributions of the microbiome to carcino-
genesis might pave the way for the development of innovative,
more ‘natural’ therapeutic approaches.
The molecular mechanisms underlying the induction of
infection-associated cancers are frequently elusive. Hit-and-run
mechanisms, implying the induction by infectious agents of the
expression of endogenous genomic mutators, ultimately
resulting in the generation of somatic mutations, have been
postulated to explain cases where oncogenic viruses are un-
detectable in fully developed cancer tissues. More frequently,
direct oncogenic mechanisms elicited by viral or bacterial
products have clearly been identiﬁed (see Megraud et al. [10],
Schinzari et al. [11], Suarez and Lecuit [12], and Pierangeli et al.
[13]).
Studies on indirect mechanisms linking infections to cancer
outgrowth and progression are largely focused on the analysis
of the interaction of infectious agents with the innate and
adaptive immune systems in the context of a chronic inﬂam-
mation process [14]. In the past decade, the ‘immune contex-
ture’ [15] of the tumour microenvironment has emerged as
critically steering the clinical course of malignant diseases. With
important exceptions [16], tumour inﬁltration by regulatory T-
cells and myeloid cells is frequently associated with a poor
prognosis [17]. In particular, alternatively activated M2 mac-
rophages producing proangiogenic and immunosuppressive
factors have been shown to promote cancer growth in a variety
of experimental models [18]. It is easy to predict that innovative
immunomodulatory treatments targeting the interaction be-
tween activated macrophages and T-cells and preventing or
reversing lymphocyte exhaustion [19] will soon be used to
attempt the modiﬁcation of the chronically inﬂamed tumour
microenvironments that are typically detectable in infection-
associated cancers.
In the context of this rapidly evolving area, we present here
four articles reviewing recent research advances in infection-
associated cancers of the highest epidemiological relevance.Clin Microbiol Infect 2015; 21: 967–968
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nisms associated with hepatitis B virus-related and hepatitis C
virus-related hepatocellular carcinoma induction by focusing on
both viral and host factors, including metabolic dysfunctions
associated with infection [11]; Pierangeli et al. analyse the
process of oncogenesis caused by different viruses (Epstein–
Barr virus, human herpesvirus type 8, human lymphotropic
virus type 1, human papilloma virus, and Merkel cell polyoma
virus) in immunocompromised patients, as compared with the
general population, thereby emphasizing the multifaceted role
of the immunity in cancer development [13]; Megraud et al.
review the direct and indirect mechanisms underlying H. pylori
infection-associated gastric cancers, and analyse the dietary
factors and genetic background favouring carcinogenesis [10];
and Suarez and Lecuit address the role of viral infection in
lymphoma, as resulting from direct oncogenesis, or emerging
within the context of chronic antigenic stimulation or human
immunodeﬁciency virus-induced immunodeﬁciency [12].
We have learned a great deal about the different mechanisms
by which infection and cancer development intersect, but much
remains to be done. It is our ﬁrm opinion that determining the
genetic variations affecting inﬂammation and immunity and
susceptibility to infections may provide novel insights into the
basic mechanisms of carcinogenesis, and may help to improve
our therapeutic intervention potential.Transparency declarationThe authors declare that they have no conﬂicts of interest.References[1] de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al.
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